We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 2,767

China’s Vice Premier Liu He to Visit Washington at End of Month to Continue Trade Talks
  • Kelley Drye & Warren LLP
  • USA, China
  • January 18 2019

Chinese Vice Premier Liu He will visit Washington on January 30-31, in connection with further discussions to resolve the ongoing trade dispute


US Government Granted Exclusion of 984 Chinese Products From 25 Tariffs
  • King & Wood Mallesons
  • USA, China
  • January 17 2019

The office of the U.S. Trade Representative (the “USTR”) has granted 984 individual product exclusion requests involving 21 separate HTS codes from


Global M&A value hits new heights in 2018 despite Q4 headwinds
  • White & Case LLP
  • USA, United Kingdom, China, European Union, Global
  • January 14 2019

Given the backdrop of growing political tensionsincluding rising protectionism around the world, a potential trade war between the world’s two


Extension of import restrictions imposed on certain archaeological material from China
  • Baker McKenzie
  • USA, China
  • January 14 2019

On January 14, 2019, US Customs and Border Protection (CBP) published in the Federal Register a final rule CBP Dec. 19-02) that amends the CBP


Section 301 Goes Global: U.S. May Soon Apply Additional Duties to Non-Chinese-Origin Goods
  • Jones Day
  • USA, China
  • January 8 2019

The United States Trade Representative ("USTR") requested comments to identify countries that fail to protect intellectual property rights or deny


Looking to 2019 and beyond - accessing the U.S. pharmabiotech market: U.S. drug inspections in China: Staying ahead of FDA enforcement trends
  • Hogan Lovells
  • USA, China
  • January 8 2019

China’s pharmaceutical manufacturing industry is amongst the largest, and, from a supply-chain perspective, one of the most important, in the world


The U.S. and China Make Progress in Trade Talks but Significant Issues Remain Unresolved
  • King & Spalding LLP
  • USA, China
  • January 8 2019

On Wednesday, January 9, 2018, U.S. and Chinese trade officials concluded three days of intensive trade negotiations that were intended to reduce the


Looking to 2019 and beyond - accessing the U.S. pharmabiotech market: Preliminary regulatory barriers life sciences acquirers face in ChinaU.S. cross-border transactions
  • Hogan Lovells
  • USA, China
  • January 8 2019

On November 8, a team of life sciences lawyers from our Washington, D.C., New York, and Beijing offices hosted a seminar in Beijing on the key


Looking to 2019 and beyond - accessing the U.S. pharmabiotech market: Considerations for structuring and bridging the valuation gap in life sciences M&A transactions
  • Hogan Lovells
  • USA, China
  • January 8 2019

Two of the main issues that parties to life sciences transactions must consider at the outset of a transaction are how to structure the deal and what


B&C Publishes Forecast for U.S. Federal and International Chemical Regulatory Policy 2019
  • Bergeson & Campbell PC
  • USA, Mexico, Middle East, Oman, Australia, Qatar, South Korea, Taiwan, United Arab Emirates, United Kingdom, Bahrain, Vietnam, OECD, Canada, Central & South America, China, European Union
  • January 8 2019

The U.S. Environmental Protection Agency (EPA) in general and the Office of Chemical Safety and Pollution Prevention (OCSPP) in particular is subject